As described, this vaccine formulation represents a powerful and simple strategy to elicit high-frequency memory CD8+ T cell responses to multiple different tumor and viral epitopes under inflammatory conditions, and the T cells it generates are potent CTLs shown to eradicate melanoma lung metastases, and lower viral loads in both Ebola and RSV model infections [34–37]. This evidence concerns the gene CD8A and melanoma.